Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab Plus Atezolizumab in Resected Stage IIB-IIIB NSCLC
NCT06267001Phase 3Terminated
- Sponsor
- Roche
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab + Tiragolumab with Atezolizumab + Placebo (2 arms). Primary endpoint: Number of Participants With Adverse Events at 16.4 months. Started Mar 2024; status: terminated.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06267001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267001.